7:30 am Breakfast & Registration

8:20 am Chair’s Opening Remarks

Exploring the Current Landscape of Neuroinflammatory Targets in Neurodegenerative Diseases

8:30 am Using Classic Neuroimmunological Targets & Applying them to Different Neuroimmunology Indications

  • Johan Luthman Executive Vice President & Head of R&D, Lundbeck A/S


  • Utilizing classic neuroimmunology targets for different indications to identify neuroinflammation in neurodegenerative disease
  • Comparing small molecule and big molecule targets for neuroinflammation to identify efficacy differences across inflammation in neurodegeneration and neuropsychiatric
  • Sharing the results of Lundbeck’s recent clinical trial to support the above

9:00 am The Pivotal Role of Glia in Neuroinflammation


  • Studying microglia and astrocytes as the central components to move towards medicating inflammatory responses in the brain
  • Looking to new therapeutic approaches to prevent Inappropriate inflammation which can lead to acute and prolonged cognitive deficits
  • Analyzing the next steps in therapeutic development for neuroinflammation with regards to neurodegenerative diseases

9:30 am Utilizing Small Molecular Inhibitors to Target & Reduce Neuroinflammation


  • Focusing on CSRR1 inhibitors to understand how to modulate microglia phenotypes similar to macrophage
  • Understanding why CSFR1 has an improved safety profile to communicate the importance of safety profiles when developing new targets for inflammation
  • Unpicking how to promote neuroprotective functions when developing therapeutics to help improve the next generation of drug development

10:00 am Panel Discussion: Targets for Neuroinflammation


  • An interactive session to allow speakers to discuss different methods of targeting neuroinflammation
  • Delving into the successes and downfalls and different targets, and their effectivity for different neurodegenerative disease profiles
  • Looking towards future targets for neuroinflammation for both neurodegeneration and neuropsychiatric disorders

10:30 am Morning Break & Networking

Delving into the Influence of the Peripheral Immune System on Neuroinflammatory Outcomes

11:00 am Leveraging Well-Understood Peripheral Immune Targets to Advance our Understanding of Microglial Biology in the CNS


  • Understanding how to modulate pathways that are well characterised into cell types will less well understood biology to expand therapeutic capabilities
  • Applying the role of the receptors for the Fc region of immunoglobulins (FcRs) and downstream Bruton’s Tyrosine Kinase (BTK), which are well-understood in the peripheral immune system, to the CNS to expand target potential for neurodegenerative diseases
  • Understanding the importance of how antibodies and immune complexes modulate microglia function in neurological diseases and antibody therapeutics which engage Fc receptors to improve therapeutic development

11:30 am Targeting the Peripheral Immune System as a Novel Therapeutic Approach in Alzheimer’s Disease


  • Targeting the PD-1/PD-L1 immune checkpoint pathway in Alzheimer’s disease, to portray a unique therapeutic approach, not limited to any specific pathologyassociated factor (e.g. amyloid or tau)
  • Utilizing studies in amyloidosis and tauopathy mouse models to highlight that our therapeutic approach activates a common mechanism of action that starts with evoking a transient immune response in the periphery, and culminates with central effects on brain pathology, local tissue inflammation, and function
  • Presenting translational pharmacology showing that IBC-Ab002 is a novel fully human anti-PD-L1 antibody, engineered with differentiating characteristics tailored to treat Alzheimer’s disease

Targets with Implications in Neuropsychiatric & Neurodegenerative Disease: Understanding Promise & Potential

12:00 pm Microglial Emerging Therapies & Targets under Clinical Trial for Neurodegenerative & Neuropsychiatric Disorders


  • Analyzing the effectivity of anti TREM2 and anti CD33 agonist antibodies currently in clinical trial to improve understanding of the neuroimmunological aspects of Alzheimer’s disease
  • Looking at small molecule P2X7 receptor antagonist, currently in Phase II clinical trial, to enhance knowledge surrounding the neuroimmunological aspects of Major Depressive Disorder
  • Delving into small molecule RIPK1 inhibitor, which is currently progressing towards Phase I clinical trial, to aid comprehension of the neuroimmunological aspects of Amytrophic Lateral Sclerosis and Alzheimer’s disease

12:30 pm Lunch & Networking

Looking Beyond Alzheimer’s to Examine Inflammation in Neurodegeneration

1:30 pm Analyzing the Role of Microglia in Neuroinflammatory Responses in MS: Insights from BTK

  • Dimitry Ofengeim Head of Precision Neurology & Neuroinflammation, Sanofi Genzyme


  • Unpicking the role of microglia in neurodegenerative diseases to help understand differing inflammatory profiles across different diseases
  • Testing molecules and hypotheses of the impact of microglia cells in neuroinflammation, to lead to the discovery of biomarkers for progressive MS
  • Using data from recent clinical trials to illustrate the above points

2:00 pm Astrocytes as Therapeutic Targets in Neurologic Diseases

  • Francisco Javier Quintana Professor of Neurology; Associate Member, Ann Romney Centre for Neurologic Diseases Brigham & Women’s Hospital; Harvard Medicine School; The Broad Institute


  • Looking at the role of astrocytes in the pathology of neurologic diseases to aid understanding of neurodegenerative disease pathology
  • Understanding the importance of cell-cell interactions in CNS pathology to aid therapeutic development for neuroinflammation
  • Showcasing the identification of candidate therapeutic targets for neurologic diseases to move forward drug development for neurodegenerative diseases

2:30 pm Afternoon Break & Networking

3:00 pm The Role of Astrocytic Protein Homeostasis in Regulating Neuroinflammation & Neurodegeneration in AD

  • LuLin Jiang Staff Scientist, Sanford Burnham Prebys Medical Discovery Institute


  • Showing how the disturbance of astrocytic protein homeostasis can induce inflammatory states of astrocytes to aid understanding of neuroinflammation in neurodegeneration
  • Highlighting how restoration of astrocytic ER homeostasis can regulate neuroinflammation to provide evidence for a means to improve neurodegeneration in AD
  • Using large cohort animal model data to provide confidence in the direction of progress

Discussing the Effect of Astrocytes in Neuroinflammatory Responses in Neurodegenerative Diseases

3:30 pm Dark Astrocytes are Characterized By their State of Cellular & Metabolic Stress In Contexts of Neurodegeneration


  • Discovering dark astrocytes in Alzheimer’s disease pathology
  • Presenting the first characterization of these cells, using a combination immunocytochemical scanning electron microscopy (chip mapping) and confocal microscopy

4:00 pm End of Conference Day Two